Objective: The objective of this study was to assess the effectiveness of human epididymis protein 4 (HE4) and cancer antigen 125 (CA125), and risk of ovarian malignancy algorithm (ROMA) in identifying type I and type II epithelial ovarian cancers (EOCs).
Methods: A cross-sectional diagnostic study was conducted of 499 Thai women older than 18 years who had clinically diagnosed pelvic masses and underwent elective surgery at our hospital between July 2012 and July 2014. Preoperative serum HE4 and CA125 levels were measured, and postoperative pathologic slides were reviewed.
Results: Of 499 Thai women enrolled in this study, 357 were noncancerous (NC), 79 had type I EOCs (EOCs-I) and 63 had type II (EOCs-II). Risk of ovarian malignancy algorithm revealed significantly better performance than HE4 and CA125 in discriminating between NC and EOCs-I (receiver operating characteristic curve and area under the curve [ROC-AUC]: ROMA, 0.86; HE4, 0.80; and CA125, 0.77), and NC and EOCs-II (ROC-AUC: ROMA, 0.97; HE4, 0.95; and CA125, 0.93). In differentiation between EOCs-I and EOCs-II (setting EOC-II as reference), ROMA yielded a better performance than HE4 and CA125 (ROC-AUC: ROMA, 0.83; HE4, 0.82; and CA125, 0.77); however, CA125 and HE4 showed higher sensitivity (CA125, 77.8%; HE4, 76.2%), whereas ROMA had the highest specificity (79.8%).
Conclusions: In women who present with pelvic masses, ROMA performed very well in distinguishing between noncancer lesions and EOCs but the combined HE4 and CA125 test was more effective in predicting EOC types.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IGC.0000000000001277 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multicenter study of ovarian cancer score for diagnosing ovarian cancer.
Gynecol Oncol
January 2025
Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China; Chongqing Specialized Medical Research Center of Ovarian Cancer, Chongqing, China; Organoid Transformational Research Center, Chongqing Key Laboratory for the Mechanism and Intervention of Cancer Metastasis, Chongqing University Cancer Hospital, Chongqing, China. Electronic address:
Background: Early detection is crucial for improving survival of patients with ovarian cancer (OC), yet current diagnostic tools lack adequate sensitivity and specificity, especially for early stage disease. The study aimed to validate the serum small extracellular vesicles (sEV) protein based Ovarian Cancer Score (OCS) in detecting OC.
Methods: This multicenter study included 1183 adult females with adnexal masses from four hospitals in China (October 2019-April 2023).
Diagnostic Utility of Metalloproteinases from Collagenase Group (MMP-1, MMP-8 and MMP-13) in Biochemical Diagnosis of Ovarian Carcinoma.
Cancers (Basel)
November 2024
Department of Population Medicine and Lifestyle Diseases Prevention, The Faculty of Medicine, Medical University of Białystok, 15-269 Białystok, Poland.
Background: Ovarian carcinoma (OC) has an unfavorable prognosis due to lack of screening and an asymptomatic course. New diagnostic methods are being sought to enable earlier diagnosis of this condition. The purpose of this study was to determine the diagnostic utility of collagenases (MMP-1, MMP-8 and MMP-13) in the diagnosis of OC compared to HE4 and CA125 and the ROMA.
View Article and Find Full Text PDFValue of miR200b and its combination with other biochemical markers in the diagnosis of epithelial ovarian cancer.
Mol Biol Rep
December 2024
Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Objective: This study aimed to analyse the diagnostic performance of miR200b in epithelial ovarian cancer (EOC) in a group of Egyptian patients and to evaluate the combined use of miR200b with other biomarkers as a reliable diagnostic and prognostic indicator of EOC.
Methods: We tested the expression of cell-free miR200b in 30 EOC patients before undergoing optimum cytoreductive surgery, 19 females with benign ovarian disease and 14 normal healthy females using quantitative real time PCR. All cases were tested for CA125, HE4 and CRP.
High-risk patient profiles for ovarian cancer: A new approach using cluster analysis of tumor markers.
J Gynecol Obstet Hum Reprod
November 2024
School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Objective: Ovarian cancer remains a leading cause of cancer-related deaths in women. Early detection improves prognosis, but current diagnostic tools still need improvement. We aimed to identify high-risk patient profiles for ovarian cancer using cluster analysis of age and tumor marker data.
View Article and Find Full Text PDFClinical Utility and Diagnostic Accuracy of ROMA, RMI, ADNEX, HE4, and CA125 in the Prediction of Malignancy in Adnexal Masses.
Cancers (Basel)
November 2024
Unit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35122 Padua, Italy.
Objective: We aimed to compare the clinical utility and diagnostic accuracy of the ADNEX model, ROMA score, RMI I, and RMI IV, as well as two serum markers (CA125 and HE4) in preoperative discrimination between benign and malignant adnexal masses (AMs).
Methods: We conducted a retrospective study extracting all consecutive patients with AMs seen at our Institution between January 2015 and December 2020. Accuracy metrics included sensitivity (SE), specificity (SP), and area under the receiver operating characteristic curve (AUC), and their 95% confidence intervals (CI) were calculated for basic discrimination between AMs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!